Jung‐Min Lee

Pharmacodynamic markers and clinical results from the phase 2 study of the <scp>SMAC</scp> mimetic birinapant in women with relapsed platinum‐resistant or ‐refractory epithelial ovarian cancer

Anne M. Noonan, Kristen Bunch, Jin‐Qiu Chen et al. · Cancer · 2015 · 106 citations · Full text

Medicine, Oncology, Pharmacology +17

Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial

Jung‐Min Lee, Richard G. Moore, Sharad Ghamande et al. · Clinical Cancer Research · 2022 · 53 citations · Full text

Medicine, Oncology, Pharmacology +15

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

Elena Giudice, Tzu‐Ting Huang, Jayakumar R. Nair et al. · Nature Communications · 2024 · 40 citations · Full text

Medicine, Oncology, Pharmacology +14

AKT1 interacts with DHX9 to Mitigate R Loop–Induced Replication Stress in Ovarian Cancer

Tzu‐Ting Huang, Chih-Yuan Chiang, Jayakumar R. Nair et al. · Cancer Research · 2024 · 28 citations · Full text

Medicine, Cancer Biology, Oncology +17

<i>BLM</i> overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant <i>BRCA</i> -mutant ovarian cancer

Nitasha Gupta, Tzu‐Ting Huang, Jayakumar R. Nair et al. · Science Translational Medicine · 2023 · 24 citations · Full text

Medicine, Oncology, Pharmacology +17